Satoru Morimoto

Project Associate Professor, Frontier Research and Education Collaboration Square at Tonomachi, Keio University*Profile is at the time of the award.

2025Inamori Research GrantsBiology & Life sciences

Research topics
Elucidation of Pathological Avoidance Mechanisms and Development of Therapeutic Strategies in Amyotrophic Lateral Sclerosis (ALS)
Keyword
Summary
Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disease characterized by the loss of both upper and lower motor neurons, with differences among motor neuron subtypes in the accumulation of abnormally phosphorylated TDP-43 and the degree of cell loss. While marked degeneration is observed in the spinal anterior horn and hypoglossal nuclei, Betz cells and oculomotor nuclei maintain relative resistance. Furthermore, reduced FOX2B expression in ALS spinal motor neurons has been shown to contribute to their vulnerability. Based on these findings, this study aims to elucidate the mechanisms of disease avoidance in specific neurons using iPS cells and patient brain/spinal cord samples, and to develop novel ALS therapies including disease-modifying therapy (DMT).

Comment

This recent selection for the Inamori Research Grants is regarded as a significant step toward elucidating the pathology of ALS and establishing novel therapeutic strategies. ALS is characterized by the loss of both upper and lower motor neurons, and it is very intriguing that differences exist among motor neuron subtypes in terms of the accumulation of abnormally phosphorylated TDP-43 and cell loss. These pathological features serve as important clues for uncovering the molecular mechanisms underlying disease resistance. Moreover, our finding that decreased FOX2B expression in ALS spinal motor neurons contributes to their vulnerability presents a new therapeutic target that has been difficult to address with conventional treatments.

In this study, we will harness iPS cell technology and patient brain/spinal cord samples to conduct detailed analyses of the mechanisms by which specific neurons evade pathology, aiming to develop innovative ALS therapies, including disease-modifying therapy (DMT). With this grant, we will actively incorporate cutting-edge technologies and strengthen our research framework through a multifaceted approach to address the root causes of ALS. In doing so, we aspire to significantly contribute to improving the quality of life for ALS patients and advancing treatment, in close collaboration with domestic and international research partners.

Find other recipients

Biology & Life sciences